Krystal Biotech (NASDAQ:KRYS) Posts Quarterly Earnings Results, Beats Expectations By $0.23 EPS

Krystal Biotech (NASDAQ:KRYS) issued its quarterly earnings data on Wednesday. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23, Zacks reports. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $156.69 on Wednesday. The company’s fifty day moving average is $157.98 and its two-hundred day moving average is $175.42. Krystal Biotech has a 52-week low of $107.50 and a 52-week high of $219.34. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of 88.53 and a beta of 0.84.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 14.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have commented on KRYS shares. Chardan Capital reiterated a “buy” rating and set a $212.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup boosted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $206.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).